title: In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody.
abstract: Overexpression of epidermal growth factor receptor (EGFR) has been correlated with tumor resistance to cytotoxic agents, including radiation (T. Akimoto et al., Clin. Cancer Res., 5: 2884-2890, 1999), and thus is a candidate target for anticancer treatment. This study investigated whether treatment with C225 anti-EGFR antibody would improve tumor response to radiotherapy. Nude mice bearing 8-mm-diameter A431 tumor xenografts in the hind leg were treated with C225 antibody, 18 Gy of single-dose local tumor irradiation, or both. C225 was given i.p. at a dose of 1 mg/mouse 6 h before irradiation or 6 h before and 3 and 6 days after irradiation. Delay in tumor growth was the treatment end point. C225 dramatically improved the efficacy of local tumor irradiation, particularly when multiple injections of C225 were administered. Tumor radioresponse was enhanced by a factor of 1.59 by a single dose and by a factor of 3.62 by a doses of C225. Histological analyses of tumors revealed that C225 caused a striking increase in central tumor necrosis associated with hemorrhage and vascular thrombosis when combined with radiotherapy. In addition, C225 induced heavy tumor infiltration with granulocytes, increased tumor cell terminal differentiation, and inhibited tumor angiogenesis. We conclude that C225 anti-EGFR antibody enhances tumor radioresponse by multiple mechanisms that may involve direct and indirect actions on tumor cell survival.
authors.affiliation: Department of Experimental Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Houston 77030, USA. lmilas@mdanderson.org
authors.forename: L
authors.initials: L
authors.lastname: Milas
authors.forename: K
authors.initials: K
authors.lastname: Mason
authors.forename: N
authors.initials: N
authors.lastname: Hunter
authors.forename: S
authors.initials: S
authors.lastname: Petersen
authors.forename: M
authors.initials: M
authors.lastname: Yamakawa
authors.forename: K
authors.initials: K
authors.lastname: Ang
authors.forename: J
authors.initials: J
authors.lastname: Mendelsohn
authors.forename: Z
authors.initials: Z
authors.lastname: Fan
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects / Q000528:radiation effects; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D000068818:Cetuximab; D003131:Combined Modality Therapy; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D006801:Humans; D008297:Male; D051379:Mice; D008819:Mice, Nude; D009336:Necrosis; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D014183:Transplantation, Heterologous
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D011993:Recombinant Fusion Proteins; D066246:ErbB Receptors; D000068818:Cetuximab